AI assistant
HAEMONETICS CORP — Director's Dealing 2024
May 21, 2024
31565_dirs_2024-05-21_2a153be8-623d-4873-b81b-0f2e7bd8a5bb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-05-17
Reporting Person: Basil Michelle L (EVP and General Counsel)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-05-17 | Common Stock | S | 1073 | $95.00 | Disposed | 29352 | Direct |
| 2024-05-17 | Common Stock | F | 669 | $95.73 | Disposed | 28683 | Direct |
| 2024-05-17 | Common Stock | A | 4178 | — | Acquired | 32861 | Direct |
| 2024-05-20 | Common Stock | S | 1604 | $95.08 | Disposed | 31257 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-05-17 | Non-qualified Stock Option (Right to Buy) | $95.73 | A | 9183 | Acquired | 2031-05-17 | Common Stock (9183) | Direct |
Footnotes
F1: Transaction pursuant to an existing 10b5-1 trading plan dated December 13, 2023 (fully executed as of December 14, 2023).
F2: This number includes unvested restricted stock units ("RSUs") previously reported.
F3: Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I.
F4: The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest in three equal annual installments beginning on the first anniversary of the date of grant.
F5: Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested.
F6: Option vests in annual increments of 25% beginning on the first anniversary of the date of grant.